



Updated Monthly

August 10, 2022

THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:



Questions?

Liz Powell, Esq., MPH

lpowell@G2Gconsulting.com

www.G2Gconsulting.com



@G2Gconsulting



TABLE OF CONTENTS

Aging	2
Air Force Office of Scientific Research	2
Army Applications Lab	3
Army Research Laboratory	3
Army Research Office	3
Artificial Intelligence & Machine Learning	3
Asthma and Allergic Diseases	4
BARDA	4
Bioengineering	5
Biomaterials	5
Biomedical Research	5
Cancer	6
Cannabis Research	12
Cardiovascular and Pulmonary Health	13
Central Nervous System	13
Chronic Disease	13
Chronic Pain & Pain Management	13
Cognitive and Brain Health	16
Coronavirus	20
DARPA	20
Defense Threat Reduction Agency	20
Diagnostics	21
Down Syndrome	21
Endocrine and Metabolic Diseases	21
Energy Science	22
Genomics	23
Global Health	23
Health IT	23
Healthcare Disparities	24
HIV/AIDS	24
Immunology & Infectious Disease	25
Lupus	27

Maternal and Pediatric Health	27
Medical Countermeasures	28
Mental Health	29
National Science Foundation	30
National Virtual Biotechnology Laboratory	30
Office of Naval Research	31
Osteoporosis	31
Parkinson's Disease	31
Patient-Centered Research	31
Precision Medicine	33
Public Health	34
Rare Diseases	34
Reconstructive Transplant	35
Regenerative Medicine	35
Reproductive Health	35
Research Resources	36
Small Business Development	36
Substance Use Disorder	38
Traumatic Brain Injury	41
US Air Force Academy	41
US Army Combat Capabilities Development Command	41
US Army Research Institute	42
US Military Academy	42
US Navy	42
USAMRDC Extramural BAA	43
USSOCOM Extramural R&D	43
Vision Health	43
Warfighter Medical Optimization Division	43



August 19, 2022 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 10-10:30am EDT (FREE and open to all) then from 10:30-11am EDT (premium service and private consultation for G2G and GBG customers). Click [here](#) to register.

Going to MHSRS? Maximize your participation! Learn how to engage effectively with the military and government. Join G2G for a [Final Prep for MHSRS](#) webinar on August 17 at noon EDT. Click [here](#) to register.

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING (1)		
1.	Pre-Announcement: Healthy Aging: Optimizing Physical and Mental Functioning Across the Aging Continuum – Cycle 3 2022 (PCORI)	The Healthy Aging Targeted PCORI Funding Announcement will solicit applications for CER studies that focus on different phases of the aging continuum and aim to achieve one or more of the following four goals: maintaining function and independence; facilitating chronic disease management; supporting individuals with significant functional impairment; reducing caregiving burden and improving quality of life. https://www.pcori.org/funding-opportunities/announcement/healthy-aging-optimizing-physical-and-mental-functioning-across-aging-continuum-cycle-3-2022	Up to \$5 million, for up to 5 years	System opens: 9/7/22 Letter of intent: 10/4/22 Proposal: 1/10/23
		AIR FORCE OFFICE OF SCIENTIFIC RESEARCH (2)		
2.	Air Force Office of Scientific Research Broad Agency Announcement (DoD/Air Force) FA9550-18-S-0003	This BAA’s focus is on research areas that offer significant and comprehensive benefits to national warfighting and peacekeeping capabilities. These areas are organized and managed in two scientific branches: Engineering and Information Sciences (RTA) and Physical and Biological Sciences (RTB). https://www.grants.gov/web/grants/view-opportunity.html?oppId=305996	Dependent upon proposal	Proposals accepted on a rolling basis
3.	Research Interests of the Air Force Office of Scientific Research (DoD/Air Force) FA9550-21-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. The Engineering and Complex Systems team leads the discovery and development of the fundamental and integrated science that advances future air and space flight. The Chemistry and Biological Sciences Team is responsible for research activities in fundamental chemistry, biology, mechanics, and biophysics research. https://www.grants.gov/web/grants/view-opportunity.html?oppId=334084	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY APPLICATIONS LAB (1)		
4.	Army Applications Lab BAA for Disruptive Applications (DoD/Army) W911NF-19-S-0004	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi- domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. https://www.grants.gov/web/grants/view-opportunity.html?oppld=315517	Dependent upon proposal	Proposals accepted through 5/1/24 Pre-proposal is required
		ARMY RESEARCH LABORATORY (1)		
5.	Army Research Laboratory Broad Agency Announcement for Basic and Applied Scientific Research (DoD/Army) W911NF-17-S-0003-11	The ARL BAA seeks proposals for research based on the following S&T campaigns: Computational Sciences, Materials Research, Sciences for Maneuver, Information Sciences, Sciences for Lethality and Protection, Human Sciences, and Assessment and Analysis. Proposals are sought for cutting-edge innovative research that could produce discoveries with a significant impact to enable new and improved Army technologies and related operational capabilities and related technologies. https://www.grants.gov/web/grants/view-opportunity.html?oppld=292896	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/22
		ARMY RESEARCH OFFICE (2)		
6.	Army Research Office Broad Agency Announcement for Fundamental Research (DoD/Army) W911NF-17-S-0002-07	ARL's strategy is based on eleven Foundational Research Competencies: Biological and Biotechnology Sciences; Electromagnetic Spectrum Sciences; Energy Sciences; Humans in Complex Systems; Mechanical Sciences; Military Information Sciences; Network, Cyber and Computational Sciences; Photonics, Electronics, and Quantum Sciences; Sciences of Extreme Materials; Terminal Effects; and Weapons Sciences. These competencies are structured to create discovery, innovation, and transition of technologies for Army transformational overmatch. https://www.grants.gov/web/grants/view-opportunity.html?oppld=292877	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/22
7.	Army Research Office Broad Agency Announcement Staff Research Program (DoD/Army) W911NF20S0003	The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. Research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences. https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf	Dependent upon proposal	Proposals accepted on a rolling basis until 2/19/25
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (3)		
8.	Pre-Announcement: Advanced Training in AI for Precision Nutrition Science Research (AIPrN) (T32) (NIH) NOT-OD-22-168	This FOA will support new institutional research training programs in AI for precision nutrition (AIPrN) that will focus on integration of the domains of precision nutrition, AI including machine learning (ML), systems biology, systems science, "Big Data," and computational analytics. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-168.html	Up to \$400,000	Estimated post date: 8/16/22 Estimated proposal date: 10/31/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING		
9.	Transformative Artificial Intelligence and Machine Learning Based Strategies to Identify Determinants of Exceptional Health and Life Span (R21/R33 CT Not Allowed) (NIH/NIA) RFA-AG-23-033	This FOA invites applications seeking to develop novel, transformative AI/ML strategies and computer automation to integrate, extract, and interpret multi-omic data sets from human exceptional longevity (EL) cohorts and multiple non-human species that display a wide variation in life span, and to decipher the relationships between DNA, RNA, proteins, metabolites, and other cell variables, as well as links to disease risks and exceptionally healthy aging. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-23-033.html	Up to \$150,000 per year, for up to 2 years (R21) Up to \$350,000 per year, for up to 3 years (R33)	Letter of intent: 9/21/22 Proposal: 10/21/22
10.	AI/Tech + Aging Pilot Awards (NIH/NIA/AITC)	This program will fund demonstration technology projects that utilize artificial intelligence (AI) approaches and technology to improve care and health outcomes for older Americans, including persons with Alzheimer's disease and related dementias (AD/ADRD) and their caregivers. https://www.a2collective.ai/pilotawards	Up to \$200,000 per year	Proposal: 8/15/22
		ASTHMA AND ALLERGIC DISEASES (1)		
11.	Allergy and Asthma Statistical and Clinical Coordinating Center (AA-SCCC) (U01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-22-054	This FOA solicits applications for an Allergy and Asthma Statistical and Clinical Coordinating Center (AA-SCCC) to provide a broad range of support critical for design, development, execution, and analysis of clinical research in allergic diseases and asthma. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-054.html	Up to \$9 million per year, for up to 5 years	Letter of intent: 10/30/22 Proposal: 11/30/22
		BARDA (2)		
12.	BARDA's Division of Research, Innovation & Ventures (DRIVE) Easy Broad Agency Announcement (EZ-BAA) (HHS/BARDA) BAA-20-100-SOL-00002	BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #5: ReDirect (Repurposing Drugs in Response to Chemical Threats); AOI #8: Bringing Laboratory Testing to the Home; AOI #9: Digital Health Tools for Pandemic Preparedness.; AOI #14: Healing Lungs (Simpler, Safer Lung Support for Severe ARDS patients). https://sam.gov/opp/of026c861ae84ef499be99d7604ef3db/view https://drive.hhs.gov/partner.html	Up to \$750,000, per award	Proposals accepted on a rolling basis until 2/3/23
13.	BARDA Broad Agency Announcement (HHS/BARDA) BARDABAA	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antibacterials; Radiological, Nuclear & Chemical Threat MCMs; Burn Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics. https://sam.gov/opp/550c21c541ac4c5ea14a52997a84a65d/view https://www.medicalcountermeasures.gov/barda/barda-baa	Dependent upon proposal	White papers: 12/15/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOENGINEERING (3)		
14.	Pre-Announcement: Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed/Required) (NIH/NCI/NINDS) NOT-CA-22-110 NOT-CA-22-111	These FOAs will aim to encourage collaborations between the life and physical sciences to foster the development of innovative technology, model, technique, design, or method that has the potential for significant impact on biomedical research by infusing principles and concepts from the quantitative science. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-110.html https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-111.html	Up to \$500,000	Estimated post date: 8/17/22 Estimated proposal date: 10/17/22
15.	Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) (NIH) PAR-22-123	The objectives are to establish these promising bioengineering tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. https://grants.nih.gov/grants/guide/pa-files/PAR-22-123.html	Dependent upon proposal, for up to 5 years	Letter of intent: 8/26/22 Proposal: 9/29/22
		BIOMATERIALS (3)		
16.	Data-Driven Tools to Accelerate the Clinical Translation of Novel Dental, Oral, and Craniofacial Biomaterials (R61/R33/R42/R44 - Clinical Trial Not Allowed) (NIH/NIDCR) RFA-DE-23-006 (R61/R33) RFA-DE-23-007 (R42) RFA-DE-23-008 (R44)	These FOAs seek to accelerate the clinical translation of novel biomaterials for dental, oral, and craniofacial (DOC) applications through development and implementation of advanced data-driven tools designed to overcome critical bottlenecks in research and development (R&D) cycles that lead to delays in regulatory evaluations and translation to human use. https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-23-006.html (R61/R33) https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-23-007.html (R42) https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-23-008.html (R44)	Up to \$200,000 per year, for up to one year (R61/Phase I) Up to \$750,000 per year, for up to 3 years (R33/Phase II)	Letter of intent: 10/10/22 Proposal: 11/9/22
		BIOMEDICAL RESEARCH (2)		
17.	Technology Development Research for Establishing Feasibility and Proof of Concept and Focused Technology Research and Development (R21/R01 – CT Not Allowed) (NIH/NIGMS/NIA/NCI) PAR-22-126 (R21) PAR-22-127 (R01)	PAR-22-126 supports exploratory research leading to the development of innovative technologies for biomedical research. PAR-22-127 supports projects that focus solely on the development of technologies with the potential to enable acquisition of biomedical knowledge. Outcomes or products of the proposed project should significantly advance the current state of the art and be sufficiently characterized for application in addressing a broad range of biomedical research questions. https://grants.nih.gov/grants/guide/pa-files/PAR-22-126.html (R21) https://grants.nih.gov/grants/guide/pa-files/PAR-22-127.html (R01)	Up to \$275,000, for up to 2 years (R21) Dependent upon proposal, for up to 5 years (R01)	Proposal: 10/16/22 (R21) Proposal: 10/5/22 (R01)



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER (44)		
18.	Pre-Announcement: Provision of Training and Technical Assistance to Enhance Comprehensive Cancer Control Outcomes (CDC/NCCDPHP) CDC-RFA-DP23-2317	The purpose of this NOFO is to fund up to 4 recipients with expertise, capacity, and national reach in cancer control and prevention to provide training and technical assistance (TTA) to National Comprehensive Cancer Control Program (NCCCP) recipients and cancer coalitions. The aim of the TTA is to provide tools and skills to help NCCCP recipients succeed at convening and supporting a cancer coalition in implementing the jurisdictional cancer plan using policy, system, environmental (PSE) change approaches. https://www.grants.gov/web/grants/view-opportunity.html?oppld=342808	Up to \$825,000	Estimated post date: 3/30/23 Estimated proposal date: 5/29/23
19.	Pre-Announcement: Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required) (NIH/NCI) NOT-CA-22-091	This FOA will invite applications on pragmatic trials across the cancer control continuum. The overarching goal of this FOA is to support the development of a more robust, representative, and diverse collection of evidence-based cancer-related interventions. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-091.html	Up to \$500,000 per year, for up to 2 years (UG3) Up to \$750,000 per year, for up to 4 years (UH3)	Estimated post date: 11/30/22 Estimated proposal date: 2/17/23
20.	Pre-Announcement: Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required) (NIH/NCI) NOT-CA-22-113	ROBIN Centers created through this FOA will join an agile and effective national radiation oncology network infrastructure that collectively address critical hypothesis-based translational research knowledge gaps on the biological basis of responses in cancer patients who undergo radiation treatments. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-113.html	Up to \$1 million per year, for up to 5 years	Estimated post date: 8/15/22 Estimated proposal date: 10/3/22
21.	Basic Research in Cancer Health Disparities (R01/R21/R03 Clinical Trial Not Allowed) (NIH/NCI) PAR-21-322 (R01) PAR-21-323 (R21) PAR-21-324 (R03)	All grants will investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. https://grants.nih.gov/grants/guide/pa-files/PAR-21-322.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-21-323.html (R21) https://grants.nih.gov/grants/guide/pa-files/PAR-21-324.html (R03)	Dependent on proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21) Up to \$50,000 per year, for up to 2 years (R03)	Proposal: 10/5/22 (R01) Proposal: 10/16/22 (R21/R03)



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
22.	Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01/21 Clinical Trial Not Allowed) (NIH/NCI) PAR-22-061 (R01) PAR-22-062 (R21)	These FOAs support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. https://grants.nih.gov/grants/guide/pa-files/PAR-22-061.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-062.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Proposal: 10/5/22 (R01) Proposal: 10/16/22 (R21)
23.	Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01/R21 Clinical Trial Not Allowed) (NIH/NCI) PAR-22-083 (R01) PAR-22-084 (R21)	Applications to this FOA should include, when possible, relevant biospecimens to evaluate associated risk factors and liver cancer risk. Applications that include an investigation on viral-associated liver cancer must provide strong rationale that outlines the added innovation or new knowledge to be gained from the current evidence of viral-associated liver cancer etiology. https://grants.nih.gov/grants/guide/pa-files/PAR-22-083.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-084.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Proposal: 10/5/22 (R01) Proposal: 10/16/22 (R21)
24.	Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01/R21 Clinical Trial Not Allowed) (NIH/NCI/NIDCR) PAR-22-085 (R01) PAR-22-086 (R21)	These FOAs solicit grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. https://grants.nih.gov/grants/guide/pa-files/PAR-22-085.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-086.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Proposal: 10/5/22
25.	Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) (NIH/NCI) PAR-22-099	This FOA aims to encourage investigator-initiated research efforts aimed at the development, characterization and implementation of state-of-the-art biomimetic tissue-engineered technologies for cancer research as well as cancer diagnosis, treatment, and prevention strategies. Tissue-engineered in vitro and ex vivo systems that reflect the pathology and physiology of human disease are needed within the existing continuum of cancer models as new tools for understanding cancer biology. https://grants.nih.gov/grants/guide/pa-files/PAR-22-099.html	Dependent upon proposal, for up to 5 years	Letter of intent: 9/5/22 Proposal: 10/5/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
26.	Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional) (NIH/NCI) PAR-22-131	This FOA will support the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other omic information and/or meta data obtained from platforms including but not limited to lower resolution diagnostic acquisitions and systemic biomarker results to high resolution single-cell analytics / imaging applied to the characterization of heterogeneous cell populations within tumor for improving current approaches for: (1) the early detection of organ confined premetastatic aggressive cancer, and, (2) identifying precancerous lesions associated with the development of a subsequent lethal phenotype. https://grants.nih.gov/grants/guide/pa-files/PAR-22-131.html	Dependent upon proposal, for up to 5 years	Proposal: 10/5/22
27.	Research Projects in Physical Sciences-Oncology (U01 Clinical Trial Optional) (NIH/NCI) PAR-22-147	The PS-OPs, individually and as a collaborative Network along with other PS-OPs and Centers, will support transdisciplinary research that: (1) establishes a physical sciences perspective within the cancer research community; (2) facilitates team science and field convergence at the intersection of physical sciences and cancer research; and (3) collectively tests physical sciences-based experimental and theoretical concepts of cancer and promotes innovative solutions to address outstanding questions in cancer research. https://grants.nih.gov/grants/guide/pa-files/PAR-22-147.html	Up to \$400,000 per year, for up to 5 years	Letter of intent: 10/1/22 Proposal: 11/1/22
28.	Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01/R21 Clinical Trial Optional) (NIH/NCI) PAR-22-164 (R01) PAR-22-165 (R21)	These FOAs support meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication pilot interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. https://grants.nih.gov/grants/guide/pa-files/PAR-22-164.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-165.html (R21)	Up to \$500,000 per year, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Letter of intent: 9/5/22 Proposal: 10/5/22 (R01) Letter of intent: 9/16/22 Proposal: 10/16/22 (R21)
29.	Cancer Prevention and Control Clinical Trials Planning Grant Program (R34/U34 Clinical Trials Optional) (NIH/NCI) PAR-22-173 (R34) PAR-22-174 (U34)	Through these FOAs, NCI intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. https://grants.nih.gov/grants/guide/pa-files/PAR-22-173.html (R34) https://grants.nih.gov/grants/guide/pa-files/PAR-22-174.html (U34)	Up to \$600,000, for up to 3 years Dependent upon award mechanism	Letter of intent: 9/25/22 Proposal: 10/5/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
30.	NCI Clinical and Translational Exploratory/Developmental Studies (R21 CT Optional) (NIH/NCI) PAR-22-216	This FOA supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. https://grants.nih.gov/grants/guide/pa-files/PAR-22-216.html	Up to \$275,000, for up to 2 years	Proposal: 10/10/22
31.	Biology of Bladder Cancer (R01/R21 Clinical Trial Optional) (NIH/NCI) PAR-22-218 (R01) PAR-22-219 (R21)	These FOAs encourage applications that investigate the biology and underlying mechanisms of bladder cancer. While substantial progress has been made in identifying etiological factors, mutated genes and molecular profiles of bladder cancers, our mechanistic knowledge about bladder tumorigenesis and bladder cancer biology is relatively limited. https://grants.nih.gov/grants/guide/pa-files/PAR-22-218.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-219.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Letter of intent: 9/5/22 Proposal: 10/5/22 (R01) Letter of intent: 9/16/22 Proposal: 10/16/22 (R21)
32.	Advanced Development and Validation of Emerging and Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61/R33 CT Not Allowed) (NIH/NCI) RFA-CA-22-001 (R61) RFA-CA-22-002 (R33)	RFA-CA-22-001 solicits R61 grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. RFA-CA-22-002 invites R33 grant applications where major feasibility gaps for the technology or methodology have been overcome, but further development and rigorous validation is required. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-001.html (R61) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-002.html (R33)	\$150,000 per year, for up to 3 years (R61) \$300,000 per year, for up to 3 years (R33)	Letter of intent: 8/22/22 Proposal: 9/22/22
33.	Innovative and Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33/61 Clinical Trial Not Allowed) (NIH/NCI) RFA-CA-22-003 (R61) RFA-CA-22-004 (R33)	These FOAs solicit grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-003.html (R61) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-004.html (R33)	Up to \$150,000 per year, for up to 3 years (R61) Up to \$300,000 per year, for up to 3 years (R33)	Letter of intent: 8/22/22 Proposal: 9/22/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
34.	Patient Derived Xenograft (PDX) Development and Trial Centers (PDTCs) Network and PDX Data Commons and Coordinating Center (PDCCC) (U54/U24 Clinical Trial Not Allowed) (NIH/NCI) RFA-CA-22-012 (U54) RFA-CA-22-013 (U24)	The PDXNet is a NCI program established to coordinate collaborative, large-scale development and pre-clinical testing of targeted therapeutic agents in patient-derived models to advance the vision of cancer precision medicine. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-012.html (U54) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-013.html (U24)	Up to \$810,000 per year, for 5 years (U54) Up to \$650,000 per year, for 5 years (U24)	Letter of intent: 10/1/22 Proposal: 11/1/22
35.	Global Implementation Science for Equitable Cancer Control (GlobalISE Cancer Control, U54 Clinical Trial Optional) (NIH/NCI/NIMH) RFA-CA-22-019	This initiative will support implementation science research capacity-building activities, including research projects that identify, develop, and test innovative theory-based strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based cancer control interventions in LMICs. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-019.html	Up to \$750,000 per year, for 5 years	Letter of intent: 10/8/22 Proposal: 11/8/22
36.	Research to Understand and Address the Survivorship Needs of Individuals Living with Advanced Cancer (R01 Clinical Trial Optional) (NIH/NCI) RFA-CA-22-027	This FOA will support studies that aim to better understand and/or address survivorship needs for individuals living with likely incurable cancer. Specifically, this RFA is intended to solicit applications proposing 1) observational studies to understand the trajectory of physical and psychological symptoms, patterns of care, and unmet needs; and/or 2) the development and testing of interventions to improve the delivery of comprehensive survivorship care in this group of cancer survivors. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-027.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 8/30/22 Proposal: 9/30/22
37.	The Early Detection Research Network: Clinical Validation and Biomarker Characterization Centers (U01/U2C Clinical Trial Optional/Not Allowed) (NIH/NCI/NIDCR) RFA-CA-22-039 (U01) RFA-CA-22-040 (U2C)	EDRN (http://edrn.nci.nih.gov/) is an integrated infrastructure to develop and validate biomarkers and imaging methods for the detection of early-stage cancers and risk assessment. Clinical Validation Centers (CVCs) will conduct research to validate biomarkers and/or imaging methods for risk assessment and detection of early-stage cancers. BCCs will (1) discover, develop, characterize and test new biomarkers or refine existing biomarkers, (2) develop, refine and/or standardize biomarker assays, (3) provide resources and support for the validation of biomarkers developed by the EDRN, and (4) participate in collaborative projects with other laboratories and centers. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-039.html (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-040.html (U2C)	Up to \$3.69 million, for up to 5 years (U01) Up to \$3.4 million, for up to 5 years (U2C)	Proposal: 9/8/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
38.	NCI Outstanding Investigator Award (R35 Clinical Trial Optional) (NIH/NCI) RFA-CA-22-045	This award will provide long-term support to accomplished investigators with outstanding records of cancer research accomplishments who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-045.html	Up to \$600,000 per year, for up to 7 years	Letter of intent: 10/8/22 Proposal: 11/8/22
39.	FY22 Breast Cancer Breakthrough Award Levels 1 and 2 (BTA12-2) Era of Hope Scholar Award (EOHS-2) (DoD/CDMRP) W81XWH-22-BCRP-BTA12-2 W81XWH-22-BCRP-EOHS-2	Considering the current breast cancer landscape and the BCRP's mission to end breast cancer, the BCRP seeks applications that address the following overarching challenges: Prevent breast cancer; Identify determinants of breast cancer initiation, risk, or susceptibility; Distinguish deadly from non-deadly breast cancers; Conquer the problems of overdiagnosis and overtreatment; Identify what drives breast cancer growth; determine how to stop it; Identify why some breast cancers become metastatic; Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence; Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival; and Eliminate the mortality associated with metastatic breast cancer. https://cdmrp.army.mil/funding/bcrp	Up to \$3 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 9/22/22 Proposal: 10/6/22
40.	FY22 Kidney Cancer Academy of Kidney Cancer Investigators – Early-Career Scholar Award (AKCIECSA) Clinical Trial Award (CTA) Nurse-Initiated Research Award (NIRA) (DoD/CDMRP) W81XWH-22-KCRP-AKCIECSA W81XWH-22-KCRP-CTA W81XWH-22-KCRP-NIRA	Applications submitted to the FY22 KCRP should address one or more of the following Focus Areas: • Conduct basic biology research on kidney cancer. • Define the biology of rare kidney cancers and develop treatments to improve outcomes and reduce death. • Identify and develop new strategies for screening, early-stage detection, accurate diagnosis and prognosis prediction of kidney cancers. • Develop novel therapeutic strategies for the treatment of kidney cancer. • Identify and implement strategies to improve quality of life and survivorship. • Identify and implement strategies to mitigate health disparities. • Support preparation and development of the next generation of kidney cancer researchers, or cultivate collaborations in kidney cancer research or patient care. https://cdmrp.army.mil/funding/kcrp	Up to \$2 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 9/29/22 Proposal: 10/20/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
41.	FY22 Melanoma Research Program (MRP) Focused Program Award- Rare Melanomas (FPA) Melanoma Academy Scholar Award (MASA) Mid-Career Accelerator Award (MCAA) Team Science Award (TSA) (DoD/CDMRP) W81XWH-22-MRP-FPA W81XWH-22-MRP-MASA W81XWH-22-MRP-MCAA W81XWH-22-MRP-TSA	Applications submitted to the FY22 MRP must address one or more of the following Focus Areas: - Investigate topics relevant to rare melanomas that cover the entire research spectrum. - Identify and understand risk factor determinants for melanoma. - Develop prediction and surveillance tools - Understand how precursor lesions and environmental/endogenous factors influence melanomagenesis. - Develop new tools for the detection and diagnosis of melanoma, which includes easily accessible technology for physicians and dermatologists. - Identify how the tumor microenvironment impacts tumor initiation, response to therapy, progression, recurrence, and/or dormancy. - Delineate the molecular pathways that influence metastatic spread, recurrence, and/or dormancy. https://cdmrp.army.mil/funding/mrp	Up to \$2 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 9/14/22 Application: 10/5/22
42.	FY22 Peer Reviewed Cancer Research Program Behavioral Health Science Award Career Development Award – Scholar Option (DoD/CDMRP) W81XWH-22-PRCRP-BHSA-2 W81XWH-22-PRCRP-CDA-SO	The FY22 PRCRP requires all applications to answer at least one of the following Military Health Focus Areas: Environmental/exposure risk factors associated with cancer; Gaps in cancer research that may affect mission readiness: Gaps in cancer prevention, early detection/diagnosis, prognosis, and/or treatment and Gaps in quality of life and/or survivorship. Applications are encouraged to respond to the FY22 PRCRP Overarching Challenges: Prevention; Diagnostics/Prognostics; Therapeutics; Behavioral Science; Disparity; Resources. https://cdmrp.army.mil/funding/prcrp	Up to \$1 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 9/28/22 Proposal: 10/25/22
		CANNABIS RESEARCH (8)		
43.	NOSI: Promoting Mechanistic Research on Therapeutic and Other Biological Properties of Minor Cannabinoids and Terpenes (NIH) NOT-AT-22-027	This NOSI aims to promote mechanistic research of therapeutic benefits of minor cannabinoids and terpenes in the cannabis plant. The mechanisms and processes underlying potential contribution of minor cannabinoids and terpenes to symptoms relief and functional restoration may be very broad encompassing different pathological conditions and diseases. https://grants.nih.gov/grants/guide/notice-files/NOT-AT-22-027.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 7/1/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CARDIOVASCULAR AND PULMONARY HEALTH (1)		
44.	NOSI: Respiratory Complications of the Muscular Dystrophies (R01) (NIH) NOT-HL-22-025	This NOSI supports further elucidation of respiratory phenotypes in humans; research to optimize pulmonary function testing and existing respiratory therapies in humans; and mechanistic and translational research, including in vitro and in animal models, that examines respiratory muscle response to gene therapies and other therapeutic strategies in the muscular dystrophies. https://grants.nih.gov/grants/guide/notice-files/NOT-HL-22-025.html	Dependent upon proposal, for up to 5 years	Proposal: 10/5/22
		CENTRAL NERVOUS SYSTEM (2)		
45.	Global Brain and Nervous System Disorders Research Across the Lifespan (R01/R21 Clinical Trials Optional) (NIH) PAR-21-311 (R01) PAR-21-319 (R21)	These FOAs encourage grant applications for the exploration and the conduction of innovative, collaborative research projects with low- and middle-income country (LMIC) institutions/scientists on brain and other nervous system function and disorders throughout life, relevant to LMICs.. https://grants.nih.gov/grants/guide/pa-files/PAR-21-311.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-21-319.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$125,000 per year, for up to 2 years (R21)	Letter of intent: 10/15/22 Proposal: 11/15/22
		CHRONIC DISEASE (1)		
46.	Pre-Announcement: Telehealth to Optimize Management of Multiple Chronic Conditions among Vulnerable Populations in Primary Care – Cycle 3 2022 (PCORI)	This FOA is soliciting applications that respond to the following question: What is the comparative clinical effectiveness of different approaches to incorporating access to and use of telehealth to optimize management of multiple chronic conditions in primary care, particularly among vulnerable populations? Applications should focus on community-dwelling individuals with multiple chronic conditions and should be powered to allow for conclusions regarding one or more vulnerable populations of interest https://www.pcori.org/funding-opportunities/announcement/telehealth-optimize-management-multiple-chronic-conditions-among-vulnerable-populations-primary-care-cycle-3-2022	Up to \$10 million, for up to 5 years	System opens: 9/7/22 Letter of intent: 10/4/22 Proposal: 1/10/23
		CHRONIC PAIN & PAIN MANAGEMENT (21)		
47.	NOSI: NCCIH High Priority Pain Research (NIH/NCCIH) NOT-AT-22-007	The NCCIH is inviting applications to focus on the following topic areas: Basic/Mechanistic, Translational, or Clinical Research on Pain Related to Sickle Cell Disease; Basic and Mechanistic Understanding of Myofascial Pain; Fundamental Science of Biophysical Force-Based Interventions to Prevent or Manage Chronic Pain; Identifying Novel Therapeutic Targets of Pain for Non-Addictive Natural Products; The Science of Music Therapies to Enhance Pain Management; Multi-Component Pain Management Intervention Development; Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth. https://grants.nih.gov/grants/guide/notice-files/NOT-AT-22-007.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 12/15/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CHRONIC PAIN & PAIN MANAGEMENT		
48.	NOSI: Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery (NIH) NOT-NS-22-095	This NOSI aims to encourage the development, validation, and replication of animal models that recapitulate the phenotypic and physiologic characteristics of a defined pain type/indication and/or disease-associated pain condition and endpoints or outcome measures that can be used therein. The goal of this NOSI is to improve the translational application of animal models and/or outcome measures for the development of non-addictive analgesics. https://grants.nih.gov/grants/guide/notice-files/not-ns-22-095.html	Up to \$750,000, for up to 3 years	Proposal: 10/18/22
49.	NOSI: HEAL Initiative: Clinical Translation of Diagnostic and Therapeutic Devices via Blueprint MedTech (NIH) NOT-NS-23-002	Small businesses are encouraged to submit grant applications that propose non-clinical validation for subsequent clinical feasibility studies of medical devices for the diagnosis and treatment of pain and opioid use disorder (OUD). Applications supporting the development and translation of groundbreaking neurotechnologies that fit within the mission of the HEAL Initiative are encouraged. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-23-002.html	Dependent upon proposal and award mechanism	Letter of intent: 9/18/22 Proposal: 10/18/22
50.	Pre-Announcement: HEAL Initiative Integrated Basic and Clinical Team-based Research in Pain (RM1 Clinical Trial Optional) (NIH/NINDS/NICHHD) NOT-NS-23-009	This FOA will solicit applications for multi-PI team-based integrated research efforts for pursuing bold, impactful, and challenging research in basic and clinical pain domains to understand the biology of specific human pain conditions as well as pain associated with diverse diseases/disorders, including mechanistic underpinning of heterogeneity and stratification of patients with specific pain conditions and co-morbidities. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-23-009.html	TBD	Estimated post date: 9/1/22 Estimated proposal due date: 11/11/22
51.	HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional/Required) (NIH) RFA-AT-23-001 RFA-AT-23-002	These FOAs solicit cooperative agreement applications to conduct multisite embedded pragmatic or implementation trials and efficacy or effectiveness clinical trials to inform the uptake of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management. Trials may propose methods to implement, improve adherence, or evaluate the effectiveness of guidelines for pain management in patients with SCD in various health care settings; and may also address the impact of these approaches on related psychological and functional outcomes to support improved overall well-being and quality of life. https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-23-001.html https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-23-002.html	Up to \$500,000 per year, for up to 2 years (UG3) Up to \$1 million per year, for up to 4 years (UH3)	Letter of intent: 10/21/22 Proposal: 11/21/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CHRONIC PAIN & PAIN MANAGEMENT		
52.	HEAL Initiative: Discovery and Functional Evaluation of Human Pain-associated Genes & Cells (U19 Clinical Trial Not Allowed) (NIH) RFA-NS-22-018	This FOA supports multidisciplinary groups of researchers to conduct collaborative, team-based science utilizing cutting-edge technologies and approaches and large-scale, high throughput tissue and single-cell analysis on primary human tissues involved in human pain processing. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-018.html	Up to \$1.5 million per year, for up to 5 years	Letter of intent: 9/11/22 Proposal: 7/7/22
53.	HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed) (NIH) RFA-NS-22-034	This FOA promotes the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-034.html	Dependent upon proposal, for up to 5 years	Letter of intent: 9/4/22 Proposal: 10/4/22
54.	HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional) (NIH) RFA-NS-22-050	This FOA aims to promote the discovery of candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials. The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-050.html	Up to \$500,000 per year, for up to 2 years (UG3) Up to \$1.5 million per year, for up to 3 years (UH3)	Letter of intent: 9/13/22 Proposal: 10/13/22
55.	HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed) (NIH) RFA-NS-22-052	The goal of this FOA is to support interdisciplinary team-based research projects to develop assays, conduct screening and early optimization work followed by pharmacokinetic, pharmacodynamic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-052.html	Up to \$1.5 million per year, for up to 5 years	Letter of intent: 9/11/22 Proposal: 10/11/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CHRONIC PAIN & PAIN MANAGEMENT		
56.	HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain (R01 Clinical Trial Not Allowed) (NIH) RFA-NS-22-070	This FOA invites research to develop, characterize, and rigorously validate non-rodent mammalian models of pain, associated outcome measures and/or endpoints that will significantly advance translational research for effective pain management. These models are expected to recapitulate molecular, cellular, pathological, behavioral, and/or cognitive aspects of human pain disorders and conditions. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-070.html	Up to \$750,000 per year, for up to 5 years	Letter of intent: 10/4/22 Proposal: 11/4/22
57.	HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional) (NIH) RFA-NS-23-003	is designed to support interdisciplinary research teams of multiple PDs/PIs to investigate the mechanism of action of pain relief by medical devices with the overall goal of optimizing therapeutic outcomes for FDA-approved or -cleared technologies. Teams are encouraged to consider objectives that will produce major advances in the understanding of pain relief by medical devices. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-003.html	Up to \$1.5 million per year, for up to 5 years	Letter of intent: 9/10/22 Proposal: 10/10/22
		COGNITIVE AND BRAIN HEALTH (20)		
58.	NOSI: BRAIN Initiative: Translation of Groundbreaking Technologies from Early-stage Development through Early Clinical Study via Blueprint MedTech (NIH) NOT-NS-22-052	This NOSI encourages the translation of the novel neurotechnologies, funded through the BRAIN Initiative and overseen by the NIH Blueprint MedTech program. Academic and Small Business Concerns (SBCs) are encouraged to submit grant applications that propose non-clinical validation for subsequent clinical feasibility studies. Applications supporting the development and translation of groundbreaking neurotechnologies that fit within the mission of the BRAIN Initiative are encouraged. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-22-052.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 6/21/24
59.	Blueprint Medtech: Small Business Translator (U44 – CT Optional), Incubator Hubs (U54 CT Not Allowed), and MedTech Translator (UG3/UH3 – CT Optional) (NIH) PAR-21-282 (U44) PAR-21-314 (U54) PAR-21-315 (UG3/UH3)	PAR-21-282 and PAR-21-315 support small businesses in pursuing translational activities and clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. PAR-21-314 supports incubator hubs to help innovators build medical devices as close to the 'final system' as possible. https://grants.nih.gov/grants/guide/pa-files/PAR-21-282.html (U44) https://grants.nih.gov/grants/guide/pa-files/PAR-21-314.html (U54) https://grants.nih.gov/grants/guide/pa-files/PAR-21-315.html (UG3/UH3)	Dependent upon proposal and award type; for up to 5 years	Letter of intent: 9/20/22 Proposal: 10/20/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
60.	Pilot, Early, and Late Stage Clinical Trials for the Spectrum of AD/ADRD and Age-Related Cognitive Decline (R01/R61 Clinical Trial Optional) (NIH/NIA) PAR-21-359 (R01) PAR-21-360 (R61)	The purpose of these FOAs is to support projects that propose to collect pilot data to support, develop, and implement early to late stage clinical trials of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and AD/ADRD across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods. https://grants.nih.gov/grants/guide/pa-files/PAR-21-359.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-21-360.html (R61)	Dependent upon proposal, for up to 5 years (R01) Up to \$325,000 per year, for up to 2 years (R61)	Proposal: 10/5/22 (R01) Proposal: 10/18/22 (R61)
61.	Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional) (NIH/NINDS) PAR-22-030	This FOA aims to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated POC data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial. PAR-22-028 provides researchers with a mechanism to access CROs/CMOs and SMEs within the URGent Network to support planning, manufacturing, and limited nonclinical therapeutic development efforts. https://grants.nih.gov/grants/guide/pa-files/PAR-22-030.html	Dependent upon proposal, for up to 2 years	Letter of intent: 9/8/22 Proposal: 10/8/22
62.	Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed) (NIH/NINDS) PAR-22-076	This FOA encourages grant applications for investigator-initiated prospective observational comparative effectiveness research. The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. https://grants.nih.gov/grants/guide/pa-files/PAR-22-076.html	Dependent upon proposal, for up to 7 years	Letter of intent: 9/18/22 Proposal: 10/18/22
63.	Global Brain and Nervous System Disorders Research Across the Lifespan (R01/R21 Clinical Trials Optional) (NIH) PAR-22-097 (R01) PAR-22-098 (R21)	These FOAs encourage research and exploratory applications proposing innovative, collaborative research projects on global neuro-health including brain and other nervous system function and disorders throughout the lifespan, relevant to Low and middle income countries (LMICs). https://grants.nih.gov/grants/guide/pa-files/PAR-22-097.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-098.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$125,000 per year, for up to 2 years (R21)	Letter of intent: 10/15/22 Proposal: 11/15/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
64.	Structural Biology of ADRDs Proteinopathies (R01 Clinical Trial Not Allowed) (NIH/NINDS/NIA) PAR-22-208	This FOA supports studies that characterize the structure of protein aggregates found in the Alzheimer's disease related dementias (ADRD) such as alpha-synuclein, Tau, TDP-43, TMEM106B, and FUS at a high, atomic-level resolution, using approaches such as cryo-electron microscopy (cryo-EM), cryo-electron tomography (cryo-ET), and nuclear magnetic resonance (NMR) spectroscopy. https://grants.nih.gov/grants/guide/pa-files/PAR-22-208.html	Dependent upon proposal, for up to 5 years	Letter of intent: 9/7/22 Proposal: 10/7/22
65.	Cellular and Molecular Mechanisms of Prion-Like Aggregate Seeding, Propagation, and Neurotoxicity in AD/ADRD (R01 Clinical Trial Not Allowed) (NIH/NINDS) PAR-23-023	This FOA solicits applications that propose mechanistic studies in animal, cell culture, and/or human tissue models to elucidate the mechanisms by which prion-like processes in AD/ADRD are initiated, propagated, and ultimately lead to neurodegeneration and circuit dysfunction. https://grants.nih.gov/grants/guide/pa-files/PAR-23-023.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 8/24/22 Proposal: 10/24/22
66.	Building Infrastructure for Precision Medicine Research on Minority Health and Disparities in AD/ADRD (UH2/UH3 CT Not Allowed) (NIH/NIA) RFA-AG-23-020	This FOA promotes collaborative research programs to support the development of research infrastructure for precision medicine approaches for minority health and health disparities in AD/ADRD. This FOA serves as a catalytic opportunity for investigators to: (1) focus on populations understudied in AD/ADRD research; (2) build resources that include neurobiological, environmental, behavioral, and social science data; and (3) initiate innovative, integrated, and expanded studies of individuals from these populations. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-23-020.html	Up to \$350,000 per year, for up to 2 years (UH2) Up to \$750,000 per year, for up to 3 years (UH3)	Letter of intent: 9/21/22 Proposal: 10/21/22
67.	BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development (UG3/UH3 CT Not Allowed) (NIH) RFA-EB-22-001	This FOA solicits applications for team-centric development and validation of non-invasive imaging technologies that could have a transformative impact on the study of brain function/connectivity. Applications are expected to turn a novel concept into a functional prototype using a UG3/UH3 phased grant mechanism. https://grants.nih.gov/grants/guide/rfa-files/RFA-EB-22-001.html	Up to \$300,000 per year, for up to 3 years (UG3) Up to \$750,000 per year, for up to 4 years (UH3)	Letter of intent: 9/13/22 Proposal: 10/13/22
68.	BRAIN Initiative: Brain Behavior Quantification and Synchronization (R61/R33 Clinical Trial Optional) (NIH) RFA-MH-22-240	This FOA supports the development and validation of next-generation tools, methods, and analytic approaches to precisely quantify behaviors and combine them with simultaneous recordings of brain activity in humans. Tools used for measuring and analyzing behavior should be multi-modal, with the appropriate accuracy, specificity, temporal resolution, and flexibility necessary for integration with existing tools used to measure and modulate the brain circuits that give rise to those behaviors. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-240.html	Dependent upon proposal, for up to 5 years	Letter of intent: 1/17/23 Proposal: 2/17/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
69.	NINDS Interdisciplinary Team Science Grant (RM1 Clinical Trial Optional) (NIH/NINDS) RFA-NS-22-036	This FOA is designed to support integrated efforts of three or more (up to six) PDs/PIs to pursue bold, impactful, and challenging research in any area within the scope of the NINDS mission. The research approach should be interdisciplinary in nature, and the research teams are expected to establish a common goal that requires collaboration, synergy, and managed team interactions. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-036.html	Dependent upon proposal, for up to 5 years	Letter of intent: 9/7/22 Proposal: 10/7/22
70.	Functional Target Validation for Alzheimer's Disease-Related Dementias (ADRDs) (R61/R33 Clinical Trial Not Allowed) (NIH/NINDS/NIA) RFA-NS-22-055	In its initial phase, this FOA provides support for up to two years (R61 stage) for the development of customized technologies, models, and protocols to modulate the expression or activity of target candidate(s) in cells and/or tissues and monitor their functional biological consequences in in vitro or in vivo disease models. Upon demonstration of technical feasibilities, a second phase (R33 stage) will carefully and reproducibly measure and cross-validate the impact of the target modulation in different modalities across collaborating laboratories using the NIH rigor and reproducibility guidelines. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-055.html	Up to \$600,000 per year, for up to 2 years (R61) Up to \$1 million per year, for up to 2 years (R33)	Letter of intent: 10/8/22 Proposal: 11/8/22
71.	Early-Stage Therapy Development for ADRD (R61/R33 Clinical Trial Not Allowed) (NIH/NIA/NINDS) RFA-NS-22-059	This FOA encourages early-stage development of novel small molecule or biologic therapeutics for NINDS mission-relevant Alzheimer's and related dementias: frontotemporal degeneration (FTD, including Pick's disease and progressive supranuclear palsy), Lewy body dementias (LBD; including dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-059.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 9/30/22 Proposal: 10/31/22
72.	Connecting Machine Readable Digital Human AD/ADRD Neuropathological Library Platforms for Advanced Analytics (U24 Clinical Trial Not Allowed) (NIH/NINDS/NIA) RFA-NS-22-062	The purpose of this initiative is to 1) develop tools, standards, and an Open-source software platform that enables a federated (multiple data repository sites with a single access portal) approach for data sharing and analysis of human digital neuropathological slides and 2) perform software testing to validate and verify that the software and tools developed can be used to perform multisite neuropathological analyses using a federated approach. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-062.html	Up to \$650,000 per year, for up to 5 years	Letter of intent: 10/4/22 Proposal: 11/4/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CORONAVIRUS (1)		
73.	Understanding the Pathophysiology and Clinical Course of New-Onset Diabetes Following COVID-19 (U01 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-22-016	This FOA invites applications to conduct a study to establish a longitudinal cohort of individuals who developed diabetes following SARS-CoV-2 infection to understand the pathophysiology and clinical course post-COVID-19 diabetes. The goals are to determine the contribution of: 1) specific pathophysiologic pathways; 2) overall health impact of the pandemic; 3) COVID-19 severity, and 4) COVID-19 treatment upon excess new onset diabetes from SARS-CoV-2 infection and response to diabetes therapy. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-016.html	Up to \$17.5 million, for up to 4 years	Letter of intent: 11/20/22 Proposal: 12/20/22
		DARPA (3)		
74.	Biological Technologies BAA (DoD/DARPA) HR001122S0034	BTO's research investment portfolio includes combating pandemic disease, innovative physiological interventions, human performance and warfighter readiness, and deep exploration of changing ecologies and environments for improving U.S. capabilities and resilience. BTO is interested in submissions related to the following topic areas: Human Performance, Materials, Sensors, Processing, Biosecurity, Biomedical, and Biodefense https://sam.gov/opp/dfeg3a5637fc419a8ea392ee949f9c79/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 4/20/23
75.	Redefining Possible - 2022 (DoD/DARPA) HR001122S0040	The Tactical Technology Office (TTO) of DARPA is soliciting executive summaries, proposal abstracts, and proposals for applied research, advanced technology development, platform demonstrations, or systems studies that aim to redefine the future of warfighting across four domains: Air, Ground, Maritime, and Space. https://sam.gov/opp/a517e20d661b431aa933e55263a2bc42/view	Up to \$1 million, for up to 18 months	Proposals accepted on a rolling basis until 6/21/23
76.	Defense Sciences Office, Office-wide (DoD/DARPA) HR001122S0041	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Global Change. https://sam.gov/opp/d99f59e0d48245e688b92af595380c79/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 6/14/23
		DEFENSE THREAT REDUCTION AGENCY (2)		
77.	FY2022-2026 DTRA Chemical / Biological Technologies BAA (DoD/DTRA) HDTRA122S0002	DTRA is seeking optimum approaches to meet technology objectives within the areas listed below, with a goal to identify and select science and technology projects that can be transitioned to joint acquisition programs: Detection – Chemical and Biological; Digital Battlespace Management; Protection – Individual and Collective; Hazard Mitigation; Threat Agent Science; Vaccines; Medical Diagnostics; Therapeutics; Chemical Medical Countermeasures; Medical Futures; and Warfighter Integration. https://sam.gov/opp/ab3a036713364a2aa02c4187e5964449/view	Dependent upon proposal	Topic 1 Submissions: 8/16/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY		
78.	Research and Development Innovations Broad Agency Announcement (DoD/DTRA) HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across three interrelated thrust areas derived from the 2019 DTRA Strategic Plan for RDT&E (plan available at https://www.dtra.mil/): • Understand the environment, threats, and vulnerabilities • Control, defeat, disable, and dispose of threats • Safeguard the force and manage consequences https://sam.gov/opp/98f9fec4443f4e5d988d2680d85c97fo/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
		DIAGNOSTICS (1)		
79.	Point-of-Care Technologies Research Network: Technology Research and Development Centers (TRDC) (U54 Clinical Trial Optional) (NIH) PAR-22-203	The POCTRN catalyzes innovation in diagnostic technologies through a network model that enhances complementary strengths and builds multidisciplinary partnerships across scientific/technological, clinical, regulatory, and commercialization domains. The POCTRN TRDCs will merge scientific and technological capabilities and expertise with clinical need and market demand to address unmet testing, monitoring, and treatment demands. https://grants.nih.gov/grants/guide/pa-files/PAR-22-203.html	Up to \$1.2 million per year, for up to 5 years	Letter of intent: 8/16/22 Proposal: 9/27/22
		DOWN SYNDROME (6)		
80.	NOSI: Community-Based Participatory Research (CBPR) Initiative in Reducing and Eliminating Health Disparities with a focus on addressing diverse representation in research on Down syndrome (R21 Clinical Trial Optional) (NIH) NOT-OD-22-142	This NOSI supports applications that propose to develop and strengthen partnerships between minority health and health disparity communities and researchers to plan the implementation of effective health interventions that will improve community health and reduce health disparities and improve health outcomes. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-142.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 3/17/25
		ENDOCRINE AND METABOLIC DISEASES (5)		
81.	Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 CT Not Allowed) (NIH) PAS-22-096	The overall objectives of the SHINE program are to catalyze discoveries in basic molecular and cellular biology that provide new insights into the pathogenesis, prevention, detection, and potential treatment of nonmalignant hematologic diseases; to attract new investigators into basic and translational hematology research; to promote productive interdisciplinary research collaborations; and to support timely, high impact, leading-edge research. https://grants.nih.gov/grants/guide/pa-files/PAS-22-096.html	Dependent upon proposal, for up to 5 years	Proposal: 10/5/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENDOCRINE AND METABOLIC DISEASES		
82.	Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in T1D Research (U01 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-21-031	This FOA encourages applications from institutions/organizations proposing the development and/or validation of targeted mass spectrometric assays for proteins and peptides of primary interest to the type 1 diabetes research community. The proposed assays should be highly reproducible, easily transferable to other laboratories, and validated in human plasma or serum. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-031.html	Up to \$700,000 per year, for up to 4 years	Letter of intent: 9/26/22 Proposal: 10/26/22
83.	Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) (U01 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-22-009	This FOA invites applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through controlled manipulation of beta cell replication or islet cell plasticity, reprogramming of non-beta cells into beta-like cells, or shielding of residual beta cell mass from the autoimmune environment. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-009.html	Up to \$600,000 per year, for up to 4 years	Letter of intent: 9/26/22 Proposal: 10/26/22
84.	Type 1 Diabetes Mellitus Stakeholder Engagement Innovation Center to Advance Health Equity (U2C Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-22-019	The SEIC-T1D will provide highly specialized research resources to support investigators by fully embedding communities, people living with T1D, and other stakeholders into the full spectrum of research activities through expert consultations and education in principles and methods of community-engaged research. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-019.html	Up to \$1.5 million per year, for up to 5 years	Letter of intent: 10/17/22 Proposal: 11/17/22
85.	Integrated Physiology of Exocrine and Endocrine Pancreas in Type 1 Diabetes (R01 - Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-22-022	This FOA will support multi-disciplinary teams to examine interactions between exocrine and endocrine pancreas to support the study of T1D. The purpose of this opportunity is to encourage integrated study of the whole pancreas to enable characterization of direct and indirect crosstalk between exocrine and endocrine compartments, and identification of the mechanisms by which that crosstalk occurs and can be disrupted in T1D and other forms of diabetes. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-022.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 1/21/23 Proposal: 2/21/23
		ENERGY SCIENCE (1)		
86.	FY 2022 Continuation of Solicitation for the Office of Science Financial Assistance Program (DoE) DE-FOA-0002562	By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio. https://www.grants.gov/web/grants/view-opportunity.html?oppId=335970	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		GENOMICS (17)		
87.	NOSI: Single-Cell Level Spatiotemporal Mapping of Dental and Craniofacial Embryogenesis (NIH/NIDDK) NOT-DE-22-003	This NOSI aims to encourage research that applies cutting edge imaging and high-throughput 'omics approaches at the single-cell level to understand the complex spatiotemporal context of the developing dental and craniofacial tissues in the embryo. https://grants.nih.gov/grants/guide/notice-files/NOT-DE-22-003.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/25
88.	Pre-Announcement: ClinGen Genomic Curation Expert Panels (U24 Clinical Trial Not Allowed) (NIH/NICHD) NOT-HD-22-036	This FOA will support teams of subject matter experts to evaluate the clinical validity of gene-disease relationships and the pathogenicity of individual genetic variants. Using standardized protocols for gene and/or variant annotation, these expert panels curate scientific evidence to systematically define the clinical relevance of genes and variants, which can then support the subsequent development of clinical practice guidelines. https://grants.nih.gov/grants/guide/notice-files/NOT-HD-22-036.html	Up to \$220,000 per year	Estimated post date: 12/30/22 Estimated proposal date: 5/27/23
		GLOBAL HEALTH (1)		
89.	FY2022 Development Innovation Ventures (USAID) APS-7200AA22APS00001	DIV sources proposals for innovations that address international development challenges and improve the lives of people living in poverty in developing countries around the world. DIV partners with innovators to save lives, reduce poverty, strengthen democracies, respond to climate change, mitigate the consequences of COVID-19, help people emerge from humanitarian crises, and more. https://www.grants.gov/web/grants/view-opportunity.html?oppId=336301	Up to \$15 million, dependent on proposal and availability of funds	Proposals accepted on a rolling basis until 10/31/22
		HEALTH IT (4)		
90.	Joint DMS/NIGMS Initiative to Support Research at the Interface of the Biological and Mathematical Sciences (DMS/NIGMS) (NIH/NSF) NSF 22-600	This FOA supports fundamental research in mathematics and statistics necessary to answer questions in the biological and biomedical sciences. https://www.nsf.gov/pubs/2022/nsf22600/nsf22600.htm	Up to \$1.2 million, for up to 3 years Dependent upon award mechanism	Proposal: 9/19/22
91.	Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 CT Optional) (NIH) PAR-22-145	This FOA seeks to support multidisciplinary research that examines the impact of leveraging health IT to reduce disparities in access to care, quality of care, patient-clinician communication, and health outcomes for populations that experience health disparities in the U.S. https://grants.nih.gov/grants/guide/pa-files/PAR-22-145.html	Dependent upon proposal, for up to 5 years	Letter of intent: 9/5/22 Proposal: 10/5/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEALTH IT		
92.	Demonstration Projects to Promote Use of Interoperable Health Records in Clinical Research (R01 Clinical Trial Not Allowed) (NIH/NIA) RFA-AG-23-019	This FOA solicits applications for 3-year demonstration projects to study the feasibility of, and develop best practices for, using interoperable health information from older adult research participants. The projects are required to collect medical information from electronic health records (EHRs) shared by participants, combine the information inside of a digital infrastructure, and create approaches to harmonize the data across patients and providers. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-23-019.html	Up to \$750,000 per year, for up to 3 years	Letter of intent: 9/18/22 Proposal: 10/18/22
93.	BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) (NIH) RFA-MH-22-220	As part of programs of building the informatics infrastructure for the BRAIN Initiative, the FOA supports several different, but related activities. These include modifying existing analysis and visualization tools to deal with BRAIN Initiative data and integrating different types of BRAIN Initiative datasets. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-220.html	Dependent upon proposal, for up to 3 years	Letter of intent: 9/14/22 Proposal: 10/14/22
		HEALTHCARE DISPARITIES (59)		
94.	NOSI: Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan (NIH) NOT-OD-22-178	This NOSI, with 30 linked grants, encourages applications proposing to test multilevel strategies and interventions to improve the uptake of evidence-based screening services across the lifespan and in populations including, but not limited to, those experiencing health disparities and those that are underserved. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-178.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/25
95.	NOSI: Addressing Evidence Gaps in Screening (NIH) NOT-OD-22-179	This NOSI, with 29 linked grants, aims to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-179.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/25
		HIV/AIDS (5)		
96.	NOSI: Opportunities for HIV Cure Interventions at the Time of ART Initiation (NIH/NIAID/NIMH) NOT-AI-22-056	This NOSI serves to identify new opportunities for cure interventions administered during active HIV infection at or near the start of antiretroviral therapy (ART) or as a potential replacement for conventional ART, with the ultimate goal of achieving a sustained ART-free HIV remission. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-22-056.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS		
97.	A Multi-omics Approach to Immune Responses in HIV Vaccination and Intervention (Po1 Clinical Trial Not Allowed) (NIH/NIAID/NIDA) RFA-AI-22-038	This FOA will support multi-disciplinary, multi-component applications proposing the use of omics technologies to advance preventative and/or therapeutic vaccinations, and/or immunomodulatory cure interventions for HIV. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-038.html	Up to \$1 million per year, for up to 5 years	Letter of intent: 9/13/22 Proposal: 10/13/22
98.	NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01/R34 Clinical Trial Optional) (NIH/NIDA) RFA-DA-23-023 (R01) RFA-DA-23-024 (R34)	These FOAs aim to stimulate new observational and intervention research; and support pilot or feasibility research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-023.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-024.html (R34)	Dependent upon proposal, for up to 5 years (R01) Up to \$450,000, for up to 3 years (R34)	Letter of intent: 10/14/22 Proposal: 11/14/22
		IMMUNOLOGY & INFECTIOUS DISEASE (7)		
99.	Pre-Announcement: Strengthening Global Capacity for Molecular Surveillance and Outbreak Response for Foodborne, Waterborne, and Fungal Diseases (CDC/NCEZID) CDC-RFA-CK23-2303	This NOFO aims to strengthen global capacity for molecular surveillance and outbreak response for foodborne, waterborne, and fungal diseases. The Surveillance and Outbreak Response strategy will include the following activities: 1) Waterborne Disease Surveillance Strengthening and Outbreak Response; 2) Genomic surveillance, data systems and outbreak response for fungal diseases; 3) Enteric disease surveillance strengthening, including case confirmation. The Capacity Building strategy will include the following activities: 1) Country-level Water, Sanitation, and Hygiene (WASH) programs capacity building; 2) Wastewater and Environmental Surveillance capacity building; 3) Regional capacity building for Whole Genome Sequencing (WGS), bioinformatics, lab diagnosis and outbreak preparedness; 4) Country-level WGS and lab diagnosis capacity building and 5) Epidemiology and Laboratory Workforce development for foodborne, waterborne, and fungal diseases. https://www.grants.gov/web/grants/view-opportunity.html?oppld=342991	TBD	Estimated post date: 2/1/23 Estimated proposal due date: 4/2/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
100.	Ecology and Evolution of Infectious Diseases (EEID) (NSF/NIH) NSF 22-620	The multi-agency EEID program supports research on the ecological, evolutionary, organismal, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease (re)emergence and transmission and testing mathematical or computational models that elucidate infectious disease systems. https://www.nsf.gov/pubs/2022/nsf22620/nsf22620.htm	Up to \$3 million, for up to 5 years	Proposal: 11/16/22
101.	Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed) (NIH/NIAID) PAR-22-223	This FOA supports mechanistic studies on host cell death pathways and their effect on immune responses to <i>Mycobacterium tuberculosis</i> (Mtb) and Mtb/HIV co-infection to identify immune targets for development of host-directed therapies. https://grants.nih.gov/grants/guide/pa-files/PAR-22-223.html	Dependent upon proposal, for up to 5 years	Proposal: 12/7/22
102.	Partnerships for Development of Vaccines Against Select Enteric Pathogens (R01 CT Not Allowed) (NIH/NIAID) RFA-AI-22-037	This FOA aims to solicit research applications for projects focused on advancing development of vaccine candidates against Enterotoxigenic Escherichia coli (ETEC), Salmonella enterica serotype Paratyphi A, and two Shigella species, Shigella flexneri and Shigella sonnei. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-037.html	Up to \$750,000 per year, for up to 5 years	Letter of intent: 8/14/22 Proposal: 9/14/22
103.	Understanding Persistent Signs and Symptoms Attributed to Post-Treatment Lyme Disease (R01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-22-046	This FOA will support research on the underlying cause(s) of signs and symptoms that may persist following a Lyme disease diagnosis and antibiotic treatment. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-046.html	Up to \$400,000 per year, for up to 5 years	Letter of intent: 10/7/22 Proposal: 11/8/22
104.	Transplantation Statistical and Clinical Coordinating Center (T-SCCC) (U01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-22-057	This FOA solicits applications for a Transplantation Statistical and Clinical Coordinating Center (T-SCCC) to provide a broad range of support critical for the design, development, execution, and analysis of clinical research carried out by multiple NIAID-supported programs in transplantation. The scope is to support the study teams with statistical design and analysis, protocol development, and final analysis of study findings. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-057.html	Up to \$9 million per year, for up to 5 years	Letter of intent: 10/30/22 Proposal: 11/30/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
105.	NIAID Clinical Data and Safety Management Center (CDSMC) (U01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-22-058	This FOA solicits applications for the NIAID CDSMC, which will support a broad range of critical support services, including data management and processing, safety and pharmacovigilance management and processing, and sample tracking systems for NIAID-funded clinical trials, integrated studies of underlying mechanisms, clinical studies, and studies to identify and validate surrogates/biomarkers of immune-mediated diseases in the areas of asthma and allergic diseases, autoimmune diseases, and transplantation. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-058.html	Up to \$9 million per year, for up to 5 years	Letter of intent: 10/30/22 Proposal: 11/30/22
		LUPUS (3)		
106.	FY22 Lupus Idea Award (IA); Impact Award (IPA); Transformative Vision Award (TVA) (DoD/CDMRP) W81XWH-22-LRP-TVA W81XWH-22-LRP-IPA W81XWH-22-LRP-IA	The FY22 Lupus Research Program includes three award mechanisms: The Idea Award, the Impact Award, and the Transformative Vision Award. Applications must address one or more of the Focus Areas listed here , appropriate to the award sought. https://cdmrp.army.mil/funding/lrp	Up to \$2.5 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 8/16/22 Proposal: 9/1/22
		MATERNAL AND PEDIATRIC HEALTH (16)		
107.	NOSI: Research to Support Regulatory Science on Infant Formula (NIH) NOT-HD-22-016	This NOSI invites investigator-initiated applications addressing major research gaps in the evidence base to support regulation of biologically active substances, components and molecules that are intended for use in infant formula. https://grants.nih.gov/grants/guide/notice-files/NOT-HD-22-016.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/23
108.	Pre-Announcement: RADx® Tech for Maternal Health Challenge (NIH/NICHD) NOT-HD-22-035	The RADx Tech for Maternal Health Challenge aims to accelerate the development of home-based and point-of-care maternal health diagnostic devices, wearables, or other remote sensing technologies to enable extension of care and ultimately reduce severe maternal morbidity and maternal mortality (SMM/MM) for individuals residing in maternity care deserts. https://grants.nih.gov/grants/guide/notice-files/NOT-HD-22-035.html	Prizes will total \$8 million	Estimated post date: 9/1/22 Estimated proposal due date: 11/1/22
109.	Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed) (NIH/NICHD) PAR-22-215	This FOA supports innovative research that will inform our understanding of the mechanisms underlying the formation of structural birth defects using animal models in conjunction with human translational/clinical approaches. Applicants are encouraged to take advantage of advances in genetics, 'omics methods, and synthetic biology, biochemical and other approaches to developmental biology research. https://grants.nih.gov/grants/guide/pa-files/PAR-22-215.html	Up to \$499,999 per year, for up to 5 years	Proposal: 10/5/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MATERNAL AND PEDIATRIC HEALTH		
110.	Pre-Announcement: Birth Defects Study To Evaluate Pregnancy exposures (BD-STEPS) (CDC/ERA) RFA-DD-23-001	This FOA will support the capacity of BD-STEPS to identify novel epidemiologic and genetic risk factors for major, structural birth defects and for stillbirths, and to provide research findings that are intended to be translated into public health prevention messages, as warranted. https://www.grants.gov/web/grants/view-opportunity.html?oppId=342111	Up to \$800,000	Estimated post date: 11/7/22 Estimated proposal date: 1/10/23
111.	NICHD Global Network for Women's and Children's Health Research: Research Units and Data Center (UG1/U24 Clinical Trial Optional) (NIH/NICHD) RFA-HD-23-008 (UG1) RFA-HD-23-009 (U24)	These FOAs support research centers partnering with institutions in low- and lower middle-income countries to conduct multi-center observational studies and randomized clinical trials evaluating disease process, health and wellness outcomes, and results from interventions in resource-constrained settings to address the major causes of maternal, neonatal, infant, and early childhood morbidity and mortality. https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-23-008.html (UG1) https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-23-009.html (U24)	Up to \$515,000 per year, for up to 7 years (UG1) Dependent upon proposal, for up to 7 years (U24)	Letter of intent: 10/29/22 Proposal: 11/29/22
		MEDICAL COUNTERMEASURES (3)		
112.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB (DoD/Army) CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/66870bda25274773b3e5fa7cfd3coe11/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
113.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) (DoD/DTRA) HDTRA1-14-24-FRCWMD-BAA	DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense. https://sam.gov/opp/da2d0850923340169b5263998efe73f6/view	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2024
114.	CCRP Initiative: CounterACT Therapeutics Discovery and Early-Stage Development (UG3/UH3 CT Not Allowed) (NIH) PAR-22-209	This FOA solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. https://grants.nih.gov/grants/guide/pa-files/PAR-22-209.html	Up to \$350,000 per year, for up to 3 years (UG3) Up to \$450,000 per year, for up to 3 years (UH3)	Letter of intent: 9/17/22 Proposal: 10/17/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MENTAL HEALTH (7)		
115.	Pre-Announcement: Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional) (NIH/NIMH) NOT-MH-22-280	This FOA will solicit applications for collaborative clinical studies not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses including when associated with HIV/AIDS. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-22-280.html	TBD	Estimated post date: 9/1/22 Estimated proposal date: 10/5/22
116.	Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R01/R34 Clinical Trial Not Allowed) (NIH/NIMH) PAR-21-316 (R01) PAR-22-082 (R34)	These FOAs encourage innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address NIMH strategic priorities to strengthen the public health impact of NIMH-supported research. https://grants.nih.gov/grants/guide/pa-files/PAR-21-316.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-082.html (R34)	Dependent on proposal, for up to 5 years (R01) Up to \$450,000, for up to 3 years (R34)	Letter of intent: 9/5/22 Proposal: 10/5/22 (R01) Letter of intent: 9/16/22 Proposal: 10/16/22 (R34)
117.	National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U01/U19 Clinical Trial Optional) (NIH/NIMH/NIAAA) PAR-22-143 (U01) PAR-22-144 (U19)	Studies appropriate for these FOAs will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders or AUD; develop and validate tools in support of experimental therapeutic studies of innovative candidates for mental disorders or AUD; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel IND-ready agents or IDE-ready devices for the treatment of mental disorders or AUD. https://grants.nih.gov/grants/guide/pa-files/PAR-22-143.html (U01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-144.html (U19)	Dependent upon proposal, for up to 5 years	Letter of intent: 9/25/22 Proposal: 10/25/22
118.	Laboratories to Optimize Digital Health (R01 Clinical Trial Required) (NIH/NIMH) PAR-22-154	This FOA is intended to support the development of digital health test beds that leverage well-established digital mental health platforms/infrastructure to rapidly refine and optimize existing evidence based digital health interventions and conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations. https://grants.nih.gov/grants/guide/pa-files/PAR-22-154.html	Dependent upon proposal, for up to 4 years	Letter of intent: 9/5/22 Proposal: 10/5/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MENTAL HEALTH		
119.	NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional) (NIH/NIMH) RFA-MH-22-185	This award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long-term career commitment to research in specific mission areas of the NIMH. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-185.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 5/20/23 Proposal: 6/20/23
		NATIONAL SCIENCE FOUNDATION (1)		
120.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) (NSF) NSF 22-551	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. Click here for project pitch details and for the full list of topics click here . https://beta.nsf.gov/funding/opportunities/small-business-innovation-research-program-phase-i-sbirsttr-phase-i	Up to \$275,000 for up to 1 year	Project pitches accepted on a rolling basis. Submission window for invited proposals: 7/1/22 to 10/26/22
		NATIONAL VIRTUAL BIOTECHNOLOGY LABORATORY (1)		
121.	Opportunities from the National Virtual Biotechnology Laboratory (NVBL) (DOE)	NVBL is a consortium of National laboratories, taking advantage of DOE user facilities, including light and neutron sources, nanoscale science centers, sequencing and bio-characterization facilities, and high-performance computer facilities, to address key challenges in responding to the COVID-19 threat. Examples include developing innovations in testing capabilities, identifying targets for medical therapeutics, providing epidemiological and logistical support, and addressing supply chain bottlenecks. https://science.osti.gov/nvbl	Dependent upon solicitation and proposal	N/A



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		OFFICE OF NAVAL RESEARCH (1)		
122.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology (DoD/Navy) N00014-22-S-B001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.onr.navy.mil/en/work-with-us/funding-opportunities/announcements	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/22
		OSTEOPOROSIS (1)		
123.	Pre-Announcement: Comparative Effectiveness of Multimodal Interventions to Prevent Osteoporotic Fractures – Cycle 3 2023 (PCORI)	Applications should respond to the following question: What is the comparative effectiveness of multimodal treatment approaches on patient-centered outcomes in people with osteoporosis and a history of fractures? Proposed studies should compare the effectiveness of pharmacological and/or nonpharmacological combination interventions. PCORI is interested in comparing combinations and/or sequences of interventions that are either in common use, have suggested efficacy, or have strong theoretical underpinnings. https://www.pcori.org/funding-opportunities/announcement/comparative-effectiveness-multimodal-interventions-prevent-osteoporotic-fractures-cycle-3-2022	Up to \$10 million, for up to 5 years	System opens: 9/7/22 Letter of intent: 10/4/22 Proposal: 1/10/23
		PARKINSON'S DISEASE (3)		
124.	FY22 Parkinson's Research Program (PRP); Early Investigator Research Award (EIRA); Investigator-Initiated Research Award (IIRA); Synergistic Idea Award (SIA) (DoD/CDMRP) W81XWH-22-PRP-EIRA W81XWH-22-PRP-IIRA W81XWH-22-PRP-SIA	Applications submitted to the FY22 PRP must address one or more of the following Focus Areas: - Biological mechanisms and biomarkers of non-motor symptoms that could lead to the development of treatments for PD. Non-motor symptoms of interest include: Cognitive, Psychiatric, Sleep, Autonomic, and Sensory dysfunctions; Fatigue. - Biological mechanisms and biomarkers of non-pharmacological interventions for non-motor symptoms in PD. https://cdmrp.army.mil/funding/prp	Up to \$3 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 8/16/22 Proposal: 9/1/22
		PATIENT-CENTERED RESEARCH (9)		
125.	Pre-Announcement: Phased Large Awards for Comparative Effectiveness Research – Cycle 3 2022 (PCORI)	This PFA invites applications for high-quality comparative clinical effectiveness research (CER) projects that will address critical decisions faced by patients, caregivers, clinicians, and stakeholders across the health and healthcare community and for which there is insufficient evidence. https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-cycle-3-2022	TBD	System opens: 9/7/22 Letter of intent: 10/4/22 Proposal: 1/10/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH		
126.	Improving Methods for Conducting Patient-Centered Outcomes Research -- 2022 Standing PFA (PCORI)	For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in Clinical Research; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-outcomes-research-2022-standing-pfa	Up to \$750,000, for up to 3 years	System opens: 9/7/22 Letter of intent: 10/4/22 Proposal: 1/10/23
127.	Pre-Announcement: Engagement Award: Building Capacity for Small Organizations to Engage in PCOR/CER -- October 2022 Cycle (PCORI)	The Engagement Award: Building Capacity for Small Organizations to Engage in PCOR/CER funding opportunity will support two-year projects that help small organizations and their communities build capacity and skills to take part in the PCOR/CER process. https://www.pcori.org/funding-opportunities/announcement/engagement-award-building-capacity-small-organizations-engage-pcorcer-october-2022-cycle	Up to \$250,000, for up to 2 years	System opens: 7/19/22 Letter of intent: 9/29/22 Proposal: 1/24/23
128.	Engagement Award: Capacity Building -- October 2022 Cycle (PCORI)	The Engagement Award: Capacity Building opportunity funds projects that build communities prepared to participate in PCOR/CER. These awards support organizations with strong ties to patients, caregivers, clinicians, and other stakeholders who have a connection to a research focus area and seek to better equip stakeholders to engage as partners in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-october-2022-cycle	Up to \$250,000, for up to 2 years	Letter of intent: 9/29/22 Proposal: 1/11/23
129.	Engagement Award: Dissemination Initiative -- October 2022 Cycle (PCORI)	The Engagement Award: Dissemination Initiative funding opportunity aims to support projects that help organizations and communities plan for or actively bring pertinent PCORI-funded research findings to their specific audiences, including relevant patients, clinicians, communities, and others, in ways that will command their attention and interest and encourage use of this information in their healthcare decision making. https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-october-2022-cycle	Up to \$250,000, for up to 2 years	Letter of intent: 9/29/22 Proposal: 1/11/23
130.	Engagement Award: Stakeholder Convening Support -- October 2022 Cycle (PCORI)	The Engagement Award: Stakeholder Convening Support funding opportunity provides support to organizations and communities to hold multi-stakeholder convenings, meetings, and conferences that include a combination of patients, caregivers, researchers, clinicians, purchasers, payers, health system leaders, and/or other stakeholders. Convenings should be designed with the active collaboration and partnership of patients, community groups, and/or other stakeholder organizations. https://www.pcori.org/funding-opportunities/announcement/engagement-award-stakeholder-convening-support-october-2022-cycle	Up to \$100,000, for up to 2 years	Letter of intent: 9/29/22 Proposal: 1/11/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH		
131.	Broad Pragmatic Studies Funding Announcement – 2022 Standing PFA (PCORI)	This PFA covers the following four priority areas: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; Communication and Dissemination Research; and Improving Healthcare Systems. Special Areas of Emphasis include: Addressing Racism, Discrimination, and Bias in Healthcare Systems and Care Delivery; Caregiver-Delivered Interventions for Intellectual and Developmental Disabilities; Optimizing Prevention and Treatment of Postpartum Hemorrhage; Visual Impairment in Older Adults https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-funding-announcement-2022-standing-pfa	Up to \$10 million, for up to 5 years Dependent upon award mechanism	System opens: 9/7/22 Letter of intent: 10/4/22 Proposal: 1/10/23
132.	Pre-Announcement: Implementation of Effective Shared Decision Making Approaches in Practice Settings – Cycle 3 2022 (PCORI)	This initiative will support projects that propose active, multi-component approaches to implementing effective shared decision making strategies that address existing barriers and obstacles to uptake and maintenance, so that these interventions are effectively and sustainably integrated into practice. The SDM strategy must have demonstrated effectiveness on patient, caregiver, or healthcare provider decision making using widely accepted metrics; the corresponding implementation approach must have potential for use and scalability beyond the targeted implementation setting. https://www.pcori.org/funding-opportunities/announcement/implementation-effective-shared-decision-making-approaches-practice-settings-cycle-3-2022	Up to \$1.5 million, for up to 3 years	System opens: 9/7/22 Letter of intent: 10/4/22 Proposal: 1/10/23
133.	Pre-Announcement: Open Competition PFA: Implementation of Findings from PCORI's Major Research Investments – Cycle 3 2022 (PCORI)	For the Cycle 3 2022 PFA, PCORI has identified the following four areas of eligible evidence: Obesity Treatment in Primary Care Settings; Nonsurgical treatment options can improve or eliminate symptoms for women with urinary incontinence (UI); Several kinds of therapy and medicines can reduce or stop symptoms for people with PTSD; The use of narrow-spectrum versus broad-spectrum antibiotics to treat children's acute respiratory tract infections (ARTIs). https://www.pcori.org/funding-opportunities/announcement/open-competition-pfa-implementation-findings-pcoris-research-investments-cycle-3-2022	Up to \$2.5 million, for up to 3 years	System opens: 9/7/22 Letter of intent: 10/4/22 Proposal: 1/10/23
		PRECISION MEDICINE (2)		
134.	Enhancing Therapeutic Gene Expression in Human Gene Therapy (FNIH) 2022-BGTC003	This RFP solicits proposals that will advance our understanding of how AAV transduces tissues and cells of clinical importance and/or develop approaches to significantly improve transduction efficiencies in such tissues and cells. https://fnih.org/sites/default/files/2022-06/BGTC%20RFP%20AAV%20Biology%20Gene%20Expression%20REVISED%20RFP%20oFINAL.pdf	Up to \$250,000 per year, for up to two years	Proposal: 8/28/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PRECISION MEDICINE		
135.	Enhancing AAV Vector Production for Human Gene Therapy (FNIH) 2022-BGTC004	This RFP solicits proposals that will advance our understanding of and/or improve the production of high-quality and high-titer recombinant AAV (rAAV) vectors for gene therapy in humans. https://fnih.org/sites/default/files/2022-06/BGTC%20RFP%20AAV%20Biology%20Vector%20Production%20REVISED%20RFP%20FINAL.pdf	Up to \$250,000 per year, for up to two years	Proposal: 8/28/22
		PUBLIC HEALTH (1)		
136.	Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 CT Optional) (NIH/NIEHS/NIMHD) PAR-22-210	This FOA encourages multidisciplinary projects to investigate the potential health risks of environmental exposures of concern to a community and to develop and implement an environmental public health action plan based on research findings. Projects supported under this program will employ community-engaged research methods to conduct research and to translate research findings into public health action. https://grants.nih.gov/grants/guide/pa-files/PAR-22-210.html	Up to \$500,000, for up to 5 years	Proposal: 10/5/22
		RARE DISEASES (4)		
137.	Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03/R21 Clinical Trial Not Allowed) (NIH/NCATS/NICHD) PAR-22-100 (R03) PAR-22-101 (R21)	The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials. https://grants.nih.gov/grants/guide/pa-files/PAR-22-100.html (R03) https://grants.nih.gov/grants/guide/pa-files/PAR-22-101.html (R21)	Up to \$50,000 per year, for up to 2 years (R03) Up to \$275,000, for up to 2 years (R21)	Letter of intent: 9/17/22 Proposal: 10/17/22
138.	Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 CT Required) (NIH/NCATS) RFA-TR-22-029	This FOA provides support for basket clinical trials of drugs targeting shared molecular etiologies in more than one rare disease, and in the process to identify and overcome challenges in adapting the oncology basket trial model to rare diseases. https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-22-029.html	Up to \$325,000, for up to 6 months (Phase I) Up to \$2 million per year, for up to 2 years (Phase II)	Letter of intent: 10/18/22 Proposal: 11/18/22
139.	Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 CT Not Allowed) (NIH) RFA-TR-22-030	This FOA is intended to jumpstart research on understudied proteins that are associated with rare diseases and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins associated with rare disease. https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-22-030.html	Up to \$100,000 for one year	Letter of intent: 9/17/22 Proposal: 10/17/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		RECONSTRUCTIVE TRANSPLANT (1)		
140.	FY22 Reconstructive Transplant Concept Award (CA) (DoD/CDMRP) W81XWH-22-RTRP-CA	The FY22 RTRP supports research of exceptional scientific merit to refine approaches for and increase access to reconstructive transplants and state-of-the-art immunotherapy. Applications must address one or more of the Focus Areas appropriate to each award. https://cdmrp.army.mil/funding/rtrp	Up to \$200,000, for up to 18 months	Pre-Application: 9/28/22 Application: 10/19/22
		REGENERATIVE MEDICINE (3)		
141.	Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials, Studies, and Planning Grant (UG3/UH3 – Clinical Trial Required/Not Allowed) (NIH) RFA-HL-23-017 (UG3/UH3) RFA-HL-23-019 (U01) RFA-HL-23-020 (R34)	The RMIP aims to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. These FOAs support applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies, contribute an enhanced understanding of stem cell product attributes, and promote data sharing. https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-017.html (UG3/UH3) https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-019.html (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-020.html (R34)	Up to \$345,000 per year, for up to 5 years (UG3/UH3) Up to \$250,000 per year, for up to 2 years (U01) Up to \$150,000 per year, for up to 2 years (R34) 1:1 cost matching required	Letter of intent: 9/2/22 Proposal: 10/6/22
		REPRODUCTIVE HEALTH (5)		
142.	Fertility Status as a Marker for Overall Health (R01 Clinical Trial Optional/R21 Clinical Trial Not Allowed) (NIH/NCI) PAR-20-281 (R01) PAR-20-282 (R21)	Data suggest that infertility is not necessarily a unique disease of the reproductive axis but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. https://grants.nih.gov/grants/guide/pa-files/PAR-20-281.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-20-282.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Letter of intent: 9/19/22 Proposal: 10/19/22
143.	Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional) (NIH/NIAID/NICHD/NIMH) PAR-22-222	This FOA supports the development of new and innovative on-demand, event-driven, and long-acting multipurpose prevention technologies (MPTs) that prevent HIV infection and pregnancy; sexually transmitted infections (STI) and pregnancy; or multiple non-HIV STI or HIV/STI MPTs in cis and trans males and females of all ages. https://grants.nih.gov/grants/guide/pa-files/PAR-22-222.html	Dependent upon proposal, for up to 5 years	Proposal: 12/7/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		REPRODUCTIVE HEALTH		
144.	Contraceptive Development Research Center (P50 Clinical Trial Optional) (NIH/NICHD) RFA-HD-23-029	This FOA intends to support and facilitate multidisciplinary approaches towards the development of new and/or improved contraceptive methods for both men and women through the formation of a Contraceptive Development Research Center. This FOA also allows the inclusion of translational studies to facilitate the pre-clinical to clinical transition and increase the likelihood of clinical success. https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-23-029.html	Up to \$1.3 million per year, for up to 3 years	Letter of intent: 11/1/22 Proposal: 12/1/22
145.	Specialized Centers of Research Excellence (SCORE) on Sex Differences (U54 Clinical Trial Optional) (NIH) RFA-OD-22-014	The Centers of Excellence will support interdisciplinary approaches to advance translational research on sex differences. Each SCORE institution should develop a research agenda bridging basic and clinical research underlying a health issue that is pertinent to improving the health of women. https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-22-014.html	Up to \$1.5 million per year, for up to 5 years	Letter of intent: 8/30/22 Proposal: 9/30/22
		RESEARCH RESOURCES (2)		
146.	Pre-Announcement: Resource-Related Research Projects for Development of Animal Models and Related Materials (R24 Clinical Trials Not Allowed) (NIH/ORIP) NOT-OD-22-188	This FOA will support resource-related research projects that are aimed at developing and characterizing new animal-based resources, improving existing resources, or acquiring deep understanding of a model system to improve the utilization, accessibility and translational values of animal models to the research community. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-188.html	TBD	Estimated post date: 9/9/22 Estimated proposal date: 10/13/22
147.	BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed) (NIH) RFA-NS-22-011	This FOA supports efforts to disseminate resources relevant to the goals of the BRAIN Initiative for integration into neuroscience research practice. The resource(s) should address compelling needs of neuroscience researchers that are otherwise unavailable or impractical in their current form. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-011.html	Dependent upon proposal, for up to 5 years	Letter of intent: 9/14/22 Proposal: 10/14/22
		SMALL BUSINESS DEVELOPMENT (8)		
148.	DOE FY23 Phase I Release 1 (DoE) DE-FOA-0002783	Topics of the DOE SBIR/STTR are include: Bioimaging, AI/ML, and bioenergy. View the full list here: https://science.osti.gov/-/media/sbir/pdf/TechnicalTopics/FY23-Phase-I-Release-1-Combined-TopicsV308032022.pdf https://science.osti.gov/-/media/grants/pdf/foas/2022/DE_FOA_0002783.pdf	Up to \$250,000	Letter of interest: 8/29/22 Proposal: 10/11/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT		
149.	Pre-Announcement: Small Business Innovation Research (SBIR) program, Phase I (HHS/ACL) HHS-2023-ACL-NIDILRR-BISA-0000	The specific purpose of NIDILRR's SBIR program is to improve the lives of people with disabilities through R/R&D products generated by small businesses, and to increase the commercial application of NIDILRR-supported research results and development products. https://www.grants.gov/web/grants/view-opportunity.html?oppld=342539	Up to \$100,000	Estimated post date: 10/14/22 Estimated proposal date: 12/14/22
150.	PHS 2022-2 Omnibus Solicitation of the NIH/CDC/FDA for (Parent SBIR/STTP [R43/R44/R41/R42] Clinical Trials Vary) (NIH/CDC/FDA) PA-22-176 PA-22-177 PA-22-178 PA-22-179	US small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) identified in these FOAs are encouraged to submit SBIR/STTP grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). https://grants.nih.gov/grants/guide/pa-files/PA-22-176.html https://grants.nih.gov/grants/guide/pa-files/PA-22-177.html https://grants.nih.gov/grants/guide/pa-files/PA-22-178.html https://grants.nih.gov/grants/guide/pa-files/PA-22-179.html	Up to \$275,766, for up to 2 years (Phase I) Up to \$1.8 million, for up to 3 years (Phase II)	Proposal: 9/5/22
151.	Small Business Innovation Research (SBIR) Contract Proposals (NIH/CDC) PHS-2023-1	5-10% of NIH and CDC SBIR awards are made through contract procurement. Contract proposals must respond to a specific topic; view the full list of topics here: https://sam.gov/opp/2903d17270974473ba2c3834a462683f/view https://sam.gov/opp/74814abeb09541088f63dobbbae3f180b/view	Up to \$500,000 per year, for up to 1 year (Phase I) Up to \$3 million, for up to 2 years (Phase II) Dependent upon agency and topic	Proposal: 11/4/22
152.	Small Business Innovation Research Program - Phase I (USDA) USDA-NIFA-SBIR-008541	The USDA SBIR program focuses on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental research, the USDA SBIR program supports small businesses in the creation of innovative, disruptive technologies and enables the application of research advancements from conception into the market. Projects dealing with agriculturally related manufacturing and alternative and renewable energy technologies are encouraged across all SBIR topic areas . https://nifa.usda.gov/sites/default/files/rfa/FY22-SBIR-Phase1-Mod-RFA-508.pdf	Up to \$181,500 for 8 months	Proposal: 10/6/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER (18)		
153.	Alcohol Health Services Research and Treatment and Recovery Research (R01/R34 Clinical Trial Optional/Required) (NIH/NIAAA) PAR-22-156 (R01) PAR-22-157 (R34) PAR-22-158 (R01) PAR-22-159 (R34)	PAR-22-156 and PAR-22-157 will broadly focus on closing the treatment gap for individuals with AUD. PAR-22-158 and PAR-22-159 will focus broadly on topics relevant for treatment of and recovery from AUD, including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery. https://grants.nih.gov/grants/guide/pa-files/PAR-22-156.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-157.html (R34) https://grants.nih.gov/grants/guide/pa-files/PAR-22-158.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-159.html (R34)	Dependent upon proposal, for up to 5 years (R01) Up to \$450,000, for up to 3 years (R34)	Letter of intent: 9/5/22 Proposal: 10/5/22 (R01) Letter of intent: 9/16/22 Proposal: 10/16/22 (R34)
154.	NIDA Program Project Grant Applications (Po1 Clinical Trial Optional) (NIH/NIDA) PAR-22-201	NIDA seeks collaborative research by multi-disciplinary teams to address critical issues of neuroscience, genetics, behavior, prevention, treatment, epidemiology, etiology, health services, HIV/AIDS and co-occurring opportunistic infections and associated consequences in substance abusing populations, medication development, or other research areas relevant to drug abuse. https://grants.nih.gov/grants/guide/pa-files/PAR-22-201.html	Dependent on proposal, for up to 5 years	Letter of intent: 8/25/22 Proposal: 9/25/22
155.	Early Liver Transplantation Cohort Study for Alcohol-associated Liver Diseases (Collaborative R01 Clinical Trial Not Allowed) (NIH/NIAAA) RFA-AA-22-003	This FOA intends to support collaborative research projects conducted by multidisciplinary teams on early liver transplantation (ELT) for alcohol-associated liver disease (ALD) patients. The research objectives of these observational clinical studies concern factors that influence the selection, management, and outcomes of ELT. https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-22-003.html	Up to \$350,000 per year, for up to 7 years	Letter of intent: 8/30/22 Proposal: 9/30/22
156.	NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 CT Optional) (NIH/NIDA) RFA-DA-23-013	This FOA invites R01 applications to conduct research that will have a major impact in identifying, developing, implementing, or testing strategies to improve outcomes related to substance misuse, with a goal of preventing, reducing, or eliminating disparities in racial and/or ethnic communities in substance use, addiction, and related health consequences, including HIV. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-013.html	Dependent upon proposal, for up to 5 years	Letter of intent: 10/14/22 Proposal: 11/14/22
157.	NIDA REI: Coordination Center to Support Racial Equity and Substance Use Disparities Research (U24 CT Not Allowed) (NIH/NIDA) RFA-DA-23-025	NIDA seeks applications for a Coordination Center to create synergy and linkages across projects funded under NIDA's REI initiative. The Center will provide coordination for collaborative products and activities while housing shared resources. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-025.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 10/15/22 Proposal: 11/15/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER		
158.	NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional) (NIH/NIDA) RFA-DA-23-026	This FOA invites applications supporting independent, early career or established scholars who self-identify as health equity, health disparities, or social determinants of health experts with the skills to make exceptionally creative contributions to the study of equity for underserved U.S. racial and/or ethnic minority groups that experience poorer outcomes related to substance use and substance use disorders. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-026.html	Up to \$700,000 per year, for up to 5 years	Letter of intent: 10/14/22 Proposal: 11/14/22
159.	NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional) (NIH/NIDA) RFA-DA-23-028	This FOA invites clinical research applications that are exploratory/developmental in nature and seek to parse the complex effects of structural racism and investigate their impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-028.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 10/14/22 Proposal: 11/14/22
160.	HEAL Initiative: Research Studies to Develop and Implement Interventions to Prevent Opioid Misuse in Community Health Centers (R61/R33 Clinical Trial Required) (NIH) RFA-DA-23-048	This initiative seeks research that will ultimately enhance the capacity of CHCs to screen patients for opioid and substance use risk and refer them to or provide opioid and other substance use prevention services. The two areas of research interest are studies to: (1) develop and test new or adapted interventions to prevent opioid misuse among patients served by community health centers (CHCs), and/or (2) develop and test implementation strategies for screening and referral to preventive interventions for misuse of opioids and other substances among patients served by CHCs. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-048.html	Up to \$350,000 per year, for up to 2 years (R61) Up to \$750,000 per year, for up to 4 years (R33)	Letter of intent: 10/8/22 Proposal: 11/8/22
161.	HEAL Initiative: Therapeutics Development for Opioid Use Disorder in Patients with Co-occurring Mental Disorders (UG3/UH3 - Clinical Trial Optional) (NIH/NIDA/NIMH/NCCIH) RFA-DA-23-049	This FOA supports the development of new therapeutic approaches for individuals with Opioid Use Disorder (OUD) and co-occurring mental disorders (COMD). Research applications may include the development of new chemical entities, new lead compounds, repurposed marketed medications, new formulations of existing medications, new behavioral therapies, therapeutic devices, and digital therapeutics. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-049.html	Dependent upon proposal, for up to 5 years	Letter of intent: 1/2/23 Proposal: 2/2/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER		
162.	HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 - Clinical Trials Optional) (NIH) RFA-DA-23-051	NIH requests applications for studies designed to develop and test sustainable, scalable interventions to prevent opioid misuse, opioid use disorder, and co-occurring mental health conditions by intervening directly on social determinants of health (SDOH). This initiative aims to build an evidence base for preventive interventions that address inequities, social risks and/or social disadvantage. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-051.html	Dependent upon proposal, for up to 5 years	Letter of intent: 1/2/23 Proposal: 2/2/23
163.	HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional) (NIH) RFA-DA-23-053 (R61/R33) RFA-DA-23-054 (R33)	There remains an urgent need for research that advances the design of stigma-free patient-centered systems of care such that people who experience addiction can recover and sustain their recovery over the long-term. These FOAs solicit applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-053.html (R61/R33) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-054.html (R33)	Up to \$300,000 per year, for up to 2 years (R61) Up to \$750,000 per year, for up to 5 years (R33)	Letter of intent: 10/14/22 Proposal: 11/14/22
164.	HEAL Initiative: Oral Complications Arising from Pharmacotherapies to Treat Opioid Use Disorders (R01/R21 Clinical Trial Not Allowed) (NIH) RFA-DE-23-015 (R01) RFA-DE-23-016 (R21)	These FOAs solicit research to better understand the biology, natural history, and directionality of oral complications associated with pharmacotherapies used to treat opioid use disorders (OUDs). https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-23-015.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-23-016.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$250,000, for up to 2 years (R21)	Letter of intent: 12/16/22 Proposal: 1/17/23
165.	Cause of Death Elucidated (CODE) in Drug Overdose Challenge (NIH/NIDA)	This Challenge is soliciting ideas for novel postmortem toxicology screening tools that would be used to inform and streamline suspected drug overdose death investigations and to improve drug specification in overdose death counts. https://www.challenge.gov/?challenge=cause-of-death-elucidated-%28code%29-in-drug-overdose	Up to \$25,000	Proposal: 9/23/22



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		TRAUMATIC BRAIN INJURY (5)		
166.	FY22 Traumatic Brain Injury and Psychological Health Clinical Trial Award (CTA); Focused Program Award (FPA) Investigator Initiated Research Award (IIRA); Patient-Centered Research Award (PCRA); Translational Research Award (TRA) (DoD/CDMRP) W81XWH-22-S-TBIPH1-CTA W81XWH-22-S-TBIPH2-FPA W81XWH-22-TBIPHRP-IIRA W81XWH-22-TBIPHRP-PCRA W81XWH-22-TBIPHRP-TRA	The TBIPHRP complements ongoing DOD efforts toward promoting a better standard of care for psychological health and traumatic brain injury in the areas of prevention, detection, diagnosis, treatment, and rehabilitation. FY22 TBIPHRP includes five awards: Clinical Trial Award, Focused Program Award, Investigator Initiated Research Award, Translational Research Award, and Patient-Centered Research Award. Applications must address one or more of the following Focus Areas, not all of which will be applicable to every award mechanism: Understand; Prevent and Assess; and Treat. https://cdmrp.army.mil/funding/tbiphrp	Up to \$5 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 8/24/22 Proposal: 9/14/22 (IIRA/PCRA/TRA) Pre-Application: 9/1/22 Invited proposal: 12/8/22 (CTA/FPA)
		US AIR FORCE ACADEMY (1)		
167.	Research Interests of the United States Air Force Academy (DoD/Air Force) USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/web/grants/view-opportunity.html?oppld=330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		US ARMY COMBAT CAPABILITIES DEVELOPMENT COMMAND (1)		
168.	US Army Combat Capabilities Development Command Broad Agency Announcement (DoD/Army) W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. https://www.grants.gov/web/grants/view-opportunity.html?oppld=327285	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		US ARMY RESEARCH INSTITUTE (1)		
169.	U.S. Army Research Institute for the Behavioral and Social Sciences (ARI) Broad Agency Announcement for Basic, Applied, and Advanced Research (DoD/Army) W911NF-18-S-0005	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://www.grants.gov/web/grants/view-opportunity.html?oppld=304462	Dependent upon proposal	Proposals accepted on a rolling basis until 4/29/23 Full proposal required
		US MILITARY ACADEMY (1)		
170.	United States Military Academy Broad Agency Announcement (DoD/USMA) W911NF-20-S-0008	This BAA identifies topics of interest to USMA departments, directorates, and research centers and institutes. Proposals are sought for cutting-edge innovative research that could produce discoveries with a significant impact to enable new and improved Army technologies and related operational capabilities and related technologies. https://www.grants.gov/web/grants/view-opportunity.html?oppld=325932	Dependent upon proposal	Proposals accepted on a rolling basis
		US NAVY (3)		
171.	FY22 Naval Air Warfare Center Aircraft Division (NAWCAD) Office-Wide Broad Agency Announcement (DoD/Navy) N00421-22-S-0001	NAWCAD has identified the research needed to address the challenges, problems, and future technology needs of the Warfighter. Research Opportunity Areas of Interest: Artificial Intelligence/Machine Learning; Data Science & Visualization; Cyber; Avionics, Sensors & Electronic Warfare; Secure Communications & Networks; Warfare Analysis; Readiness & Sustainment; Materials & Aircraft Structures; Aeromechanics; Mechanical Systems; Power & Propulsion Systems; Human Systems; Support Equipment; and Systems Engineering. https://sam.gov/opp/daa2293493bd43f69bf1ad9b716f7bb5/view	Dependent upon proposal	White papers accepted on a rolling basis until 6/1/23
172.	Broad Agency Announcement for Innovative Environmental Technologies and Methodologies (DoD/Navy) N3943022S2401	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. https://sam.gov/opp/31a0cb3fe2fc477b2f723ebe37a7d59/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 3/21/23
173.	C4ISR, Information Operations, Cyberspace Operations and Information Technology System Research, Cryogenics & Quantum (DoD/Navy) N66001-22-S-4703	Submissions in response to this announcement shall be for areas relating to the advancement of Command, Control, Communications, Computers, Intelligence, Surveillance, and Reconnaissance (C4ISR) capabilities, enabling technologies for Information Operations and Cyberspace Operations, and Information Technology systems. https://sam.gov/opp/751823f9f7724854b4bc0c6b08c4c857/view	Dependent upon proposal	White papers accepted on a rolling basis until: 6/7/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		USAMRDC EXTRAMURAL BAA (1)		
174.	USAMRDC Broad Agency Announcement for Extramural Medical Research (DoD/USAMRDC) W81XWH18SBAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; Military Operational; Clinical and Rehabilitative Medicine; Medical Biological Defense; Medical Chemical Defense; Medical Simulation and Information Sciences Research Program. https://www.grants.gov/web/grants/view-opportunity.html?oppld=297726	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/22 Full proposal by invitation
		USSOCOM EXTRAMURAL R&D (1)		
175.	Dept. of the Army, USAMRAA – BAA for Extramural Biomedical Research and Development (DoD/USAMRAA) W81XWH-18-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries, prolonged field care, human performance optimization, and canine medicine/performance. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/web/grants/view-opportunity.html?oppld=307754	Dependent upon proposal	Proposals accepted through 7/31/23 Submission of a pre-proposal is required
		VISION HEALTH (1)		
176.	NEI Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U01 Clinical Trial Required) (NIH/NEI) PAR-22-149	This FOA invites U01 applications for early-stage clinical trials that are greater than minimal risk but are not administratively complex. Projects that are administratively complex often involve several recruiting clinical centers, an independent data coordinating center and often include resource centers. https://grants.nih.gov/grants/guide/pa-files/PAR-22-149.html	Dependent upon proposal, for up to 5 years	Proposal: 9/23/22
		WARFIGHTER MEDICAL OPTIMIZATION DIVISION (1)		
177.	Airman Readiness Medical Research (ARMR) Hybrid BAA (DoD/Air Force) FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes and operational environments to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. https://www.grants.gov/web/grants/view-opportunity.html?oppld=327332	Up to \$49 million, per award	White papers accepted on rolling basis until 4/30/26

